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LETTER TO EDITOR
This letter exposes some of the many reasons why microbiota
modulation in patients with COVID-19 disease and more in
general, in all people at greatest risk of contracting SARS-CoV2
virus infections, should be taken into consideration.
Corona Virus (CoV) is a single-stranded positive-sense RNA
virus familythat is able to infect a wide range of vertebrates, birds
and mammals, including humans. In December 2019, a new
beta-coronavirus has been isolated in Wuhan, Hubei province,
China, which was found responsible of a potentially fatal
atypical pneumonia. Beta-coronaviruses belong to a subfamily of
coronaviruses that primarily cause respiratory and intestinal
diseases. To date, seven beta-coronaviruses capable of attacking
humans have been identified: Human Coronavirus 229E;
Human Coronavirus OC43; Human Coronavirus NL63;
Human Coronavirus HKU1; SARS-CoV; MERS-CoV; SARS-
CoV-2. Of these, particularly dangerous are the Severe Acute
Respiratory Syndrome (SARS) caused by Sars-CoV, and the
Middle East respiratory syndrome caused by Mers-CoV. The new
coronavirus isolated in Wuhan has been named Sars-CoV-2.
SARS-CoV-2 is found to be similar to the SARS-CoV
responsible for the epidemic SARS that occurred in 2002. An
accurate comparative analysis of the available genomic data
showed that, this virus most likely shouldn't be a laboratory
construct, and what could be likely scenarios from which SARS-
CoV-2 evolved. Researchers proposed two possibilities: i) natural
selection in an animal host before the zoonotic transfer; ii)
natural selection in humans following zoonotic transfer [1].
Today the atypical pneumonia caused by SARS-CoV-2 has
turned into a pandemic, it changed the way we live, and will
have strong economic repercussions worldwide. To date, there is
unfortunately no known specific therapy, a vaccine is not
available, and the only chance we have to stop the spread of
infection is quarantine. Several strategies for symptoms
alleviation, already in use for other infectious and non-infectious
diseases, are continuously proposed, but at the moment there
are no indications for a medical therapy of choice for
COVID-19. Master data on mortality rates clearly listed the
highest mortality rates in people over 70, in young individuals
with comorbidities, but also in younger healthcare workers. For
example, in Italy, the data updated to 16 April 2020 by the
national college of health IIS, (Istituto Superiore di Sanità),
displays 16,991 cases diagnosed among health-workers (median
age 48 years, 32% male). The high risk for health-workers is
therefore evident even at a young age for this typology of people
(Table 1).
Many studies indicate that gut microbiota has a great influence
on the status of human health and on the correct functioning of
our immune system [2-4]. On the other hand, microbiota
composition may play itself a role in triggering infections, as well
as on infections sequel [4].
In a preliminary veterinary study on the fecal microbiota
composition in healthy cats compared to Feline Coronaviruses
(FCoV)-infected cats, Meazzi S, et al. showed that in the FCoV-
positive cats, firmicutes and bacteroidetes were respectively over-
and under-represented, compared to the healthy cats microbiota,
demonstrating a possible correlation between microbiota and
coronavirus infections in animals [5].
Even if respiratory symptoms such as cough and dyspnoea and
inflammatory symptoms such as fever are the most frequent
clinical manifestation in patients infected with SARS-CoV-2,
also intestinal involvement has emerged from data collected on
patients' symptoms. A recent document by the Italian Federation
of Digestive System Diseases Society (FISMAD) reports that a
non-negligible number of SARS-CoV-2 infected patients have
diarrhoea, nausea, vomiting and/or abdominal discomfort, at
the beginning or even before respiratory symptoms. The same
document also indicates that the virus SARS-CoV-2 uses the
ACE2 protein as a receptor, which is expressed in the lung,
kidney, and gastrointestinal tract [6,7]; Viral RNA is
demonstrable in 29-53% of the faeces samples collected in
COVID-19 patients; possible oro-faecal transmission may
continue after respiratory tract viral clearance [8]. Recently some
studies have examined the possible variations of the intestinal
microbiota in relation to COVID-19 [9-11]. We have not enough
data to say with certainty that modulation of the gut microbiota
could play a therapeutic role in the treatment of COVID-19, but
maybe targeting microbiota composition could represent an
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adjuvant therapeutic option, that will supports patients recovery,
or it can also be considered an index of potential risk-factor to
be taken into account in prevention, especially in people at risk,
such as old people and the most exposed health personnel. As a
matter of fact, during the epidemic critical phases, as in the case
of the recent SARS-CoV-2 pandemic, hospitals and
consequently doctors and nurses are under strong pressure, both
psychological (they must face a much higher than normal
mortality rate) and physiological (greater work performance). In
fact, tight shift work and sleep loss and circadian misalignment
inevitably lead to changes in the gut microbiota [12]. The
National Commission for Chinese Health and the National
Administration of Traditional Chinese Medicine include the
use of probiotics to maintain the gut microbiota balance in their
recommendations for the treatment of patients with severe
COVID-19. This indicates that the Chinese government and
first-line medical personnel take in serious consideration the
role that the gut microbiota plays in the COVID-19 infection.
Furthermore, the extensive use of antibiotics, which is especially
diffused in the most virus-affected countries such as Italy, Spain
and France, corroborate the idea of a gut microbiota’s role in
COVID-19, as antibiotics are indeed well known to induce an
intestinal dysbiosis status, leading to immune system
malfunctioning. Regarding the choice of probiotics, it must be
remembered that not all probiotics act in the same way.
Gabryszewski SJ, et al. identified and characterized an effective
Lactobacillus-mediated innate immune shield, which may
ultimately serve as critical and long-term protection against viral
respiratory infection in the absence of specific antiviral vaccines
[13].
The comorbidities reported among SARS-CoV-2 positive deaths,
such as diabetes, hypertension, atrial fibrillation, dementia and
stroke, are pathologies cured by metformin, statins, PPIs (Proton
Pump Inhibitors), psychiatric drugs, all drugs with the ability to
modify the gut microbiota’s composition. Also the advanced age
of the majority of patients with severe COVID-19, especially the
ones who do not overcome viral pneumonia, could also be
linked to gut microbiota, as it is well known that in elderly
people gut microbiota is depleted, especially in terms of
biodiversity. Considering that the main way of entry of the
SARS-CoV-2 is the nasal mucosa, it is worthy of interest that
several studies indicate that patients affected by virus airway
infections are often associated to having a specific nasal
microbiota and, vice versa, specific nasal microbiota seems to be
associated to a more severe outcome of the airway infection
[14-16]. It is very likely that the presence of SARS-CoV-2 exerts a
strong selective pressure able to have an effect on the microbiota
structure of the upper airways and intestine districts, as well as
for the microbiota structure to exert an influence on SARS-
CoV-2 infection outcome. Modifications in respiratory tract and
gut districts have recently been linked to alterations in immune
responses and to disease development in the lung [17,18]. The
existence of a "gut-lung axis" has been recently strengthened by
several studies [19]. Brown and collaborators showed that lung
microbiota protect versus Streptococcus pneumoniae and Klebsiella
pneumoniae respiratory infections, by priming pulmonary
production of granulocyte-macrophage colony-stimulating factor
(GM-CSF), by IL-17 and Nod2 stimulus [20]. An increased
morbidity and mortality, during K. pneumoniae, S. pneumoniae or
P. aeruginosa acute lung infection, was observed in germ-free
mice [20,21]. Recent studies conducted in mice with a gut
dysbiosis induced by antibiotic treatment, revealed that alveolar
macrophages were less reactive to stimulus and showed a
reduced phagocytic capacity [22]. It is possible that the
microbiota acts on macrophages by the release of short-chain
fatty acids (SCFAs), known to have wide ranging effects on
immune cell function [23]. It has been reported that the SCFA
butyrate can repress the expression IL6, IL12b, and Nos2 by
colonic macrophages [24,25], while propionate can decrease
macrophage stimulation in vitro [26]. The control of infectious
diseases by macrophage activation plays an important role.
Numerous environmental features seem to control macrophage
differentiation and function [27,28] and, among those, gut and
lung microbiota seem both to play an equally important role in
controlling infectious diseases. From this brief discussion it is
evident that not only the intestinal, but also the nasal
microbiota could be involved in COVID-19 and its course. In a
recent study [29] it was highlighted as an efficient immune
system, capable of early adaptive immune responses, might
correlate with a better clinical outcome in the case of a SARS-
CoV-2 patient.
As up to date we have no certainty, studies aimed at recognizing
intestinal/nasal microbial ecosystem changes in patients with
COVID-19 are urgent and highly necessary. Results will greatly
improve our knowledge and help us prescribe more appropriate
pro/prebiotic supporting therapies. Nevertheless, the urgency of
the present situation, together with the numerous evidences
supporting the nasal and gut microbiota role in COVID-19,
should suggest the immediate use of pro/prebiotic therapies, as
a therapeutic support in these patients.
Table 1: Distribution of cases and deaths in health-workers. (Data
source: https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-
sorveglianza-integrata-COVID-19_16-aprile-2020.pdf) Epidemiology for
public health-Istituto Superiore di Sanità-National Update April 16,
2020).
Age class Cases Deceased
years N % N %
18-29 1.622 9,6 0 0,0
30-39 2.857 16,9 2 3,3
40-49 4.782 28,2 4 6,7
50-59 5.757 34,0 16 26,7
60-69 1.84 10,9 26 43,3
70-79 95 0,6 12 20,0
Total 16.953  60  
In critical emergency cases, such as those that are occurring
around the world these days, where it is not possible to reduce
stress levels, a properly designed diet (ad personam), the use of
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specific probiotics and prebiotics, and a microbiological analysis
on the health status of the intestinal microbiota of health-
personnel, doctors and nurses, could help reduce the level of
risk for these types of professionals.
The data in this table, from a recent ISS report, show that, in
certain critical situations, also young healthcare workers can be
exposed to the risk of contracting SARS-CoV-2 infection, much
more than their coetaneous in the rest of the population.
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